RxDoctor Payments Data

Mohamed Tom, MD

Neurology · Charlotte, NCNPI 1801102587

Payments from drug & device makers

$12,570in general payments, 2019–2025

Across 65 payments — averaging $193.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$8K
  • Livanova USA, Inc.$2K
  • DIXI Medical USA Corp$729
  • UCB, Inc.$291
  • Greenwich Biosciences, Inc.$190
  • Teva Pharmaceuticals USA, Inc.$165
  • plus $641 from 15 others

What the payments were for

  • Speaking & faculty fees$6,57352%
  • Travel & lodging$2,99824%
  • Food & beverage$2,99924%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,570 in reported general payments places this provider in the 70th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$65,333
Medicare patients
320
Services billed
571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam37$58,311
Aimovig AutoinjectorErenumab-Aooe56$42,731
Nurtec OdtRimegepant Sulfate20$26,247
UbrelvyUbrogepant14$15,393
NayzilamMidazolam12$10,727
Lacosamide136$10,092
Clobazam31$9,589
EliquisApixaban12$6,943
Oxcarbazepine60$5,560
Levetiracetam227$4,709
Lamotrigine ErLamotrigine23$3,356
Divalproex Sodium ErDivalproex Sodium20$2,395
Levetiracetam ErLevetiracetam44$2,279
Lamotrigine78$1,543
Carbamazepine16$1,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$291$69,03849 claims
AbbVieUbrelvy$153$15,39314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →